Last reviewed 2026-04-23 · How we verify

ANX007

ANX007 is an anti-Aβ oligomer antibody targeting the aggregation of amyloid-beta oligomers in the brain.

ANX007 is an anti-Aβ oligomer antibody targeting the aggregation of amyloid-beta oligomers in the brain. Used for Alzheimer's disease.

At a glance

Mechanism of action

ANX007 works by binding to and neutralizing amyloid-beta oligomers, which are toxic aggregates of amyloid-beta peptides that contribute to the progression of Alzheimer's disease. By reducing the levels of these oligomers, ANX007 aims to slow down or halt the disease's progression. This mechanism is thought to be key in the development of ANX007 as a potential therapeutic agent for Alzheimer's disease.

Approved indications

• Alzheimer's disease

Common side effects

• Injection site reactions
• Headache
• Fatigue

Key clinical trials

• A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Geographic Atrophy (GA) (PHASE3)
• A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Patients With Geographic Atrophy (PHASE2)
• Study of ANX007 in Participants With Primary Open-angle Glaucoma (PHASE1)
• Single-dose Study of ANX007 in Participants With Primary Open-angle Glaucoma (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• ANX007 CI brief — competitive landscape report
• ANX007 updates RSS · CI watch RSS
• Annexon, Inc. portfolio CI